Cardiovascular endocrinology A New Era in Improving Cardiovascular Outcomes

Stay informed on news, research advances, and label updates. As our understanding and treatment of vascular disease continues to evolve, patients benefit.

Vitamin D Deficiency May Indicate Cardiovascular Disease in Overweight and Obese Children
April 4, 2017 | In overweight and obese children and adolescents, vitamin D deficiency is associated with early markers of cardiovascular disease, a new study reports. The research…

Patients with Heart Failure, Subclinical Hypothyroidism Have Worse Outcomes
April 2, 2017 | Patients with more severe heart failure have higher levels of the thyroid hormones TSH and T4 and lower T3 levels, and those with higher T4 levels…

People with Higher Thyroid Hormone Levels May be at Greater Risk for Atherosclerosis
April 1, 2017 | Middle-aged and elderly people with higher free thyroxine levels may be more likely to develop atherosclerotic diseases, new research from the Netherlands…

Take Heart: New Research Strengthens the Cardio/Endocrine Connection
February 2017 | According to the Endocrine Society’s Facts and Figures report on Cardiovascular & Lipids, cardiovascular disease is the number one cause of mortality in the U.S. Although the death rate…

In Concert: Treating Diabetes & Heart Disease
January 2017 | Cardiovascular disease (CVD) is the leading cause of death for men and women of most ethnicities in the U.S., and one of the main risk factors for CVD is diabetes…

Stressed Out: New Treatment Guidelines for Primary Aldosteronism
October 2016 | A new Endocrine Society Clinical Practice Guideline calls primary aldosteronism a major public health challenge. Research shows that an excessive level of aldosterone, far from being a rare…

John W. Funder Awarded Fondation IPSEN Endocrine Regulations Prize
September 2016 | Endocrine Society member John W. Funder, MD, PhD, of Prince Henry’s Institute in Victoria, Australia, today was awarded the Fondation PSEN Endocrine Regulations Prize for his work…

FCS Support Group Launched
September 2016 | A group of concerned patients and care providers for a rare disease have announced the formation of the first-ever organization dedicated to providing education and support for people…

Matters of the Heart: The Vital Link between the Cardiovascular and Endocrine Systems
February 2016 | While it’s well known that the endocrine system plays an important role on cardiovascular function, new research from around the world solidly demonstrates the numerous links between…

Explore highlights of current education across the Endocrine Society.

Can We Improve Cardiovascular Risk in Type 2 Diabetes?
ENDO Session | No credit available
Faculty: Cecilia C. Low Wang MD; Matthew Cavender, MD, MPH; Jennifer Green, MD; and William T. Cefalu, MD
Hear the latest about underlying mechanisms of cardiovascular disease and the impact of diabetes therapies in patients with diabetes.

Creating Clarity for Very High Triglycerides Care
Online Course | 2.25 AMA PRA Category 1 Credits™
Faculty: Robert Eckel, MD; Michael Miller, MD; Harold Bays, MD; Sergio Fazio, MD, PhD; and Eliot Brinton, MD
Learn about the molecular underpinnings of disease and relationships to endocrinopathies using updated guidelines and case examples.

Trial Updates in Type 2 Diabetes
CEU Satellite Symposium | 1.0 AMA PRA Category 1 Credit™
Carol H. Wysham, MD
Summarize cardiovascular complications and risk factors and integrate updated knowledge into practice, including the latest from the EMPA-REG and LEADER trials.

Primary Hyperaldosteronism
ENDO Session | No credit available
William F Young, Jr., MD, MSc
Review email consults in a computer-based CPC to learn practical approaches to diagnosing and treating hyperaldosteronism.

Heart Health Digital Toolkit
Patient Resource | No credit available
Reviewer: Robert M. Carey, MD
Check out interactive and downloadable resources and information for patients with questions about cardiovascular health and disease.

Endocrine Facts & Figures: Cardiovascular and Lipids
Research Resource | No credit available
Advisory Panel Chair: Robert A. Vigersky, MD
Updated epidemiological data and in-depth discussion on lipid disorders, cardiovascular disease, and endocrine-related risks with current citations and expert insights.

Explore highlights of current publications across the Endocrine Society journals. Visit for more.

Associations of Vitamin D-Binding Globulin and Bioavailable Vitamin D Concentrations with Coronary Heart Disease Events: The Multi-Ethnic Study of Atherosclerosis (MESA)
JCEM | May 3, 2017
Cassianne Robinson-Cohen, Leila R. Zelnick, Andrew N. Hoofnagle, Pamela L. Lutsey, Gregory Burke, Erin D. Michos, Steven J.C. Shea, Russell Tracy, David S. Siscovick, Bruce Psaty, Bryan Kestenbaum, and Ian H. de Boer
Low 25-hydroxyvitamin D (25(OH)D) is associated with a greater risk of coronary heart disease (CHD) in individuals who are white and Chinese…

Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement
Endocrine Reviews | April 5, 2017
William F. Young, Jr., David A. Calhoun, Jacques W.M. Lenders, Michael Stowasser, and Stephen C. Textor
Hypertension affects 28.6% of adults in United States. In most, hypertension is primary (essential or idiopathic), but a subgroup of approximately 15% has secondary hypertension…

Association of TSH With Cardiovascular Disease Risk in Overweight and Obese Children During Lifestyle Intervention
JCEM | March 31, 2017
Jesse M. Rijks, Jogchum Plat, Elke Dorenbos, Bas Penders, Willem-Jan M. Gerver, and Anita C. E. Vreugdenhil
Overweight and obese children have an increased risk to develop cardiovascular diseases (CVDs) in which thyroid-stimulating hormone (TSH) has been suggested as an intermediary factor…

A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency With Severe Triglyceridemia and Pancreatitis
JCEM | February 13, 2017
Masako Ueda, Richard L. Dunbar, Anna Wolska, Tracey U. Sikora, Maria del Rosario Escobar, Naomi Seliktar, Emil deGoma, Stephanie DerOhannessian, Linda Morrell, Adam D. McIntyre, Frances Burke, Denis Sviridov, Marcelo Amar, Robert D. Shamburek, Lita Freeman, Robert A. Hegele, Alan T. Remaley, and Daniel J. Rader
Familial chylomicronemia syndrome (FCS) is a rare disorder presenting with severe hypertriglyceridemia (HTG) and recurrent pancreatitis…

Effects of Metreleptin in Pediatric Patients With Lipodystrophy
JCEM | January 23, 2017
Rebecca J. Brown, Cristina Adelia Meehan, Elaine Cochran, Kristina I. Rother, David E. Kleiner, Mary Walter, and Phillip Gorden
Lipodystrophy syndromes comprise a rare, heterogeneous group of disorders characterized by generalized or partial lack of adipose tissue and deficiency of leptin…

The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline
JCEM | October 6, 2016
Rebecca J. Brown, David Araujo-Vilar, Pik To Cheung, David Dunger, Abhimanyu Garg, Michelle Jack, Lucy Mungai, Elif A. Oral, Nivedita Patni, Kristina I. Rother, Julia von Schnurbein, Ekaterina Sorkina, Takara Stanley, Corinne Vigouroux, Martin Wabitsch, Rachel Williams, and Tohru Yorifuji
Lipodystrophy syndromes are extremely rare disorders of deficient body fat associated with potentially serious metabolic complications, including diabetes, hypertriglyceridemia, and steatohepatitis. Due to their rarity…

Posttranslational Modifications of Lipid-Activated Nuclear Receptors: Focus on Metabolism
Endocrinology | December 07, 2016
Natalia Becares, Matthew C. Gage, and Inés Pineda-Torra
Posttranslational modifications (PTMs), or the covalent modification of a protein catalyzed by enzymes, increase the functional…

Ezetimibe-Simvastatin Therapy Reduce Recurrent Ischemic Stroke Risks in Type 2 Diabetic Patients
JCEM | August 1, 2016
Chi-Hung Liu, Tien-Hsing Chen, Ming-Shyan Lin, Ming-Jui Hung, Chang-Ming Chung, Wen-Jin Cherng, Tsong-Hai Lee, and Yu-Sheng Lin
Stroke is a major cause of death and disability worldwide. Secondary prevention of ischemic stroke (IS) is important and risk factor modifications are crucial for reducing recurrence. Treatment strategies…

N-Terminal Prosomatostatin as a Risk Marker for Cardiovascular Disease and Diabetes in a General Population
JCEM | July 11, 2016
Tore Hedbäck, Peter Almgren, Peter M. Nilsson, and Olle Melander
Somatostatin inhibits a range of hormones, including GH, insulin, and glucagon, but little is known about its role in the development of cardiometabolic disease. Objective: The objective of the study…

For a complete list of Endocrine Society guidelines, visit

The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment
JCEM | March 2, 2016
John W. Funder, Robert M. Carey, Franco Mantero, M. Hassan Murad, Martin Reincke, Hirotaka Shibata, Michael Stowasser, and William F. Young Jr.
For high-risk groups of hypertensive patients and those with hypokalemia, we recommend case detection of primary aldosteronism by determining the aldosterone-renin ratio under standard conditions…

Evaluation and Treatment of Hypertriglyceridemia
JCEM | July 2, 2013
Lars Berglund, John D. Brunzell, Anne C. Goldberg, Ira J. Goldberg, Frank Sacks, Mohammad Hassan Murad, and Anton F. H. Stalenhoef
The Task Force recommends that the diagnosis of hypertriglyceridemia be based on fasting levels, that mild and moderate hypertriglyceridemia (triglycerides of 150–999 mg/dl) be diagnosed…

Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk
JCEM | January 14, 2009
James L. Rosenzweig, Ele Ferrannini, Scott M. Grundy, Steven M. Haffner, Robert J. Heine, Edward S. Horton, and Ryuzo Kawamori
Healthcare providers should incorporate into their practice concrete measures to reduce the risk of developing CVD and T2DM. These include the regular screening and identification…

For additional meetings, visit the Endocrine Society's Worldwide Endocrinology Calendar at

Clinical Endocrinology Update & Endocrine Board Review
Dates: September 23–27, 2017
Location: Chicago, Illinois, United States
Sponsor: Endocrine Society
Whether you need the latest clinical information or you’re preparing to certify or recertify for the boards, Clinical Endocrinology Update (CEU) and Endocrine Board Review (EBR) have you covered.

ENDO Bridge
Dates: October 19–22, 2017
Location: Antalya, Turkey
Sponsor: Endocrine Society, the European Society of Endocrinology, and The Society of Endocrinology and Metabolism of Turkey
EndoBridge will provide a comprehensive update in the field of endocrinology for the clinical endocrinologist. The official language of the meeting is English, but simultaneous translation will be available in Russian, Arabic, and Turkish

Keystone Symposium on Heart Failure Crossing the Translational Divide
Dates: January 14–18, 2018
Location: Keystone, Colorado, United States
Sponsor: Keystone Symposia on Molecular and Cellular Biology

ENDO 2018
Dates: March 17–20, 2018
Location: Chicago, Illinois, United States
Sponsor: Endocrine Society
ENDO is the world’s largest event for presenting and obtaining the latest in endocrine science and medicine with an extensive program covering a broad array of topics, various networking opportunities, poster sessions, updates on new products and technologies at the ENDOExpo, and more.